Dr Diane Harbison is the founder and CEO of Decipher Analytics, a precision medicine start-up company with a focus on big data projects applied to health care. Decipher Analytics aims to build a series of disease specific data commons that can break down data silos and enable better integration of data from different sources such as EHR, panomics, imaging and digital pathology. These can be used to validate drug targets, identify biomarkers and companion diagnostics and ultimately stratify patients for experimental studies and clinical trials.

A board level executive with 20 years’ experience in life sciences.  She was the Managing Director of BioCity Scotland and was responsible for getting Enterprise Area Status conferred on the BioCity site. She has a PhD and a BSc in Molecular Biology from the University of Glasgow and an MBA from Henley Business School.

Professor Jackie Hunter is Chief Executive, Clinical Programmes & Strategic Relationships. She held senior positions at global pharmaceutical organisations including GSK, Proximagen and OI Pharma Partners before joining BenevolentAI as a Director in 2016.

She brings vast academic and business experience in the biomedical and pharmaceutical sectors. She directs the application of BenevolentAI’s technology for clinical development and gives the company the insight it needs to operate its unique business model – one which sees it not only researching, but also developing the blueprint for new drugs.

An advocate for diversity and inclusion in data generation in clinical research, Peju is passionate about raising awareness about the importance of including a more diverse population in research and the potential benefits of Artificial Intelligence in enabling this.

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Maria Nelson is the Head of Open Innovation at the Digital Catapult, a national centre to accelerate digital products and ideas to market. Her passion is the acceleration the adoption of advanced digital technologies in the UK by providing support to small companies in their growth and helping large companies innovate.

Rob Wilson is a regulatory expert with over 20 years of experience within the pharmaceutical industry from early discovery to registration. He specialises in Pre-clinical and clinical Pharmacology, Modelling and Simulation (NCA, NLME, SimCYP), Discovery and pre-clinical research, DMPK, First in human studies, Animal models (behavioural and surgical), Large molecules and Respiratory medicine.

Rob’s interest in data diversity is born from a desire to utilise data more especially in the digital age and translate this into benefit to patients particularly when identifying small changes within a population or rare conditions with very low incidence rates.